Progressive Dementia with Parkinsonism and Behavioral Changes – from the First Manifestations to the Neuropathological Confirmation (a Case Study)

Czech version

Authors: V. Franková ¹; R. Matěj ^2,3; R. Rusina ^3,4
Authors‘ workplace: Psychiatrická nemocnice v Dobřanech ¹; Oddělení patologie a molekulární medicíny, Thomayerova nemocnice, Praha ²; Neurologická klinika a Centrum klinických neurověd 1. LF UK a VFN v Praze ³; Neurologické oddělení, Thomayerova nemocnice, Praha ⁴
Published in: Cesk Slov Neurol N 2015; 78/111(2): 209-214
Category: Case Report
doi: https://doi.org/10.14735/amcsnn2015209

Overview

We describe a case of a 69-year-old man with an atypical course of dementia with Parkinsonism and progressive severe behavioral abnormalities. Clinical presentation was compatible with dementia with Lewy bodies or frontotemporal dementia with Parkinsonism. The rapid and atypical progression was related to neuropathological findings of two co-morbid neurodegenerative entities. Fully developed dementia with Lewy bodies predominated, while markers of Alzheimer’s disease were also present in the brain tissue. However, their less expressed and more widespread distribution was probably related to the absence of clinical manifestations of progressive amnestic dementia, a typical symptom of Alzheimer’s disease. We retrospectively completed missing data and retraced the clinical course from the first disease manifestations to the definite neuropathological diagnosis.

Key words:
delirium –⁠ dementia with Lewy bodies –Alzheimer’s disease –⁠ frontotemporal dementia –⁠ differential diagnosis –⁠ parkinsonism

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

Sources

1. Aarsland D, Rongve A, Nore SP, Skogseth R, Skulstad S, Ehrt U et al. Frequency and case identification of dementia with Lewy bodies using the revised consensus criteria. Dement Geriatr Cogn Disord 2008; 26(5): 445 –⁠ 452. doi: 10.1159/ 000165917.

2. Sorbi S, Hort J, Erkinjuntti T, Fladby T, Gainotti G, Gurvit H et al. EFNS ‑⁠ ENS Guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol 2012; 19(9): 1159 –⁠ 1179. doi: 10.1111/ j.1468 ‑⁠ 1331.2012.03784.x.

3. Sheardová K, Hort J, Rektorová I, Rusina R. Dementia Diagnosis and Treatment in Czech Neurological and Psychiatric Practices. Cesk Slov Neurol N 2012; 75/ 108(2): 208 –⁠ 211.

4. Franková V. Frontotemporální demence –⁠ kazuistiky z klinické praxe. Psychiatr Praxi 2004; 5(3): 146 –⁠ 149.

5. Mendez MF, Shapira JS, McMurtray A, Licht E. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry 2007; 15(1): 84 –⁠ 87.

6. McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65(12): 1863 –⁠ 1872.

7. Huang Y, Halliday G. Can we clinically diagnose dementia with Lewy bodies yet? Transl Neurodegener 2013; 2(1): 4 –⁠ 12. doi: 10.1186/ 2047 ‑⁠ 9158 ‑⁠ 2 ‑⁠ 4.

8. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ,Dickson DW et al. National Institute on Aging ‑⁠ Alzheimer‘s Association guidelines for the neuropathologic assessment of Alzheimer‘s disease: a practical approach. Acta Neuropathol 2012; 123(1): 1 –⁠ 11. doi: 10.1007/ s00401 ‑⁠ 011 ‑⁠ 0910 ‑⁠ 3.

9. Parkkinen L, Pirttilä T, Alafuzoff I. Applicability of current staging/ categorization of alpha ‑⁠ synuclein pathology and their clinical relevance. Acta Neuropathol 2008; 115(4): 399 –⁠ 407. doi: 10.1007/ s00401 ‑⁠ 008 ‑⁠ 0346 ‑⁠ 6.

10. Halliday GM, Holton JL, Revesz T, Dickson DW. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol 2011; 122(2): 187 –⁠ 204. doi: 10.1007/ s00401 ‑⁠ 011 ‑⁠ 0852 ‑⁠ 9.

11. Mitolo M, Salmon DP, Gardini S, Galasko D., Enzo Grossi E,Caffarrac P. The new Qualitative Scoring MMSE Pentagon Test (QSPT) as a valid screening tool between autopsy ‑⁠ confirmed dementia with Lewy Bodies and Alzheimer’s disease. J Alz Dis 2014; 39(4): 823 –⁠ 832. doi: 10.3233/ JAD ‑⁠ 131403.